알츠하이머병에서의 우울증 = Depression in Alzheimer’s Disease

다국어 초록 (Multilingual Abstract)

Depression is one of the most common psychiatric complications of Alzheimer disease (AD), affecting from 30% to 50% of prevalence, with most estimates in the 20-30% range. Because of having a presentation in the context of AD that differs from typical early-onset depression, it is not easy one to detect and quantify reliably, and can be difficulty to differentiate depression from the other neuropsychiatric symptoms of AD. Due to the lack of large randomized trials, optimal treatment and the true degree of efficacy remains undetermined. However, these treatments can reduce adverse impact of depression on patients and caregivers. This article provides a practical discussion of the diagnosis, evaluation, differential diagnosis and treatment of depression in AD for the clinician.

참고문헌 (Reference)

1 Fuchs A, "Video rating analysis of effect of maprotiline in patients with dementia and depression" 26 : 37-41, 1993

2 Lyketsos CG, "Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS" 60 : 737-746, 2003

3 Gonzales-Salvador T, "The stress and psychological morbidity of the Alzheimer patient caregiver" 14 : 701-710, 1999

4 Mega MS, "The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease" 56 : 1388-1393, 1999

5 Cummings JL, "The neuropsychiatric Inventory : Comprehensive assessment of psychopathology in dementia" 44 : 2308-2314, 1994

6 Zweig RM, "The neuropathology of aminergic nuclei in Alzheimer’s disease" 24 : 233-242, 1988

7 Nyth AL, "The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study" 157 : 894-901, 1990

8 Cummings JL, "The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer’s disease" 6 : S64-S78, 1998

9 Rao V, "The benefits and risks of ECT for patients with degenerative dementia who also suffer from depression" 15 : 729-735, 2000

10 Tariot PN, "The behavior rating scale for dementia of the Consortium to establish a Registry for Alzheimer’s disease" 152 : 1349-1357, 1995

11 Vinkers DJ, "Temporal relation between depression and cognitive impairment in old age: prospective population based study" 329 : 881-883, 2004

12 Wilson RS, "Temporal course of depressive symptoms during the development of Alzheimer disease" 75 : 21-26, 2010

13 Chen R, "Severity of depression and risk for subsequent dementia : cohort studies in China and the UK" 193 : 373-377, 2008

14 Banerjee S, "Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial" 378 : 403-411, 2011

15 Rosenberg PB, "Sertraline for the treatment of depression in Alzheimer disease" 18 : 136-145, 2010

16 Meltzer CC, "Serotonin in aging, late-life depression, and Alzheimer’s disease: the emerging role of functional imaging" 18 : 407-430, 1998

17 Lindsay J, "Risk factors for Alzheimer’s disease : a prospective analysis from the Canadian Study of Health and Aging" 156 : 445-453, 2002

18 Cummings JL, "Reduction of behavioural disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease" 161 : 532-538, 2004

19 Dotson VM, "Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment" 75 : 27-34, 2010

20 Lyketsos CG, "Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer’s disease:initial results from the depression in Alzheimer’s disease study" 157 : 1686-1689, 2000

21 Gonzales-Salvador T, "Quality of life of patients with dementia in long-term care" 15 : 181-189, 2000

22 Steele C, "Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease" 147 : 1049-1051, 1990

23 Olin JT, "Provisional diagnostic criteria for depression of Alzheimer’s disease" 10 : 125-128, 2002

24 Olin JT, "Provisional diagnostic criteria for depression of Alzheimer disease : rationale and background" 10 : 129-141, 2002

25 Amieva H, "Prodromal Alzheimer’s disease: sucessive emergence of the clinical symptoms" 64 : 492-498, 2008

26 Hollon SD, "Prevention of relapse following cognitive therapy vsmedications in moderate to severe depression" 62 : 417-422, 2005

27 Lyketsos CG, "Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study" 288 : 1475-1483, 2002

28 Weiner MF, "Prevalence and incidence of major depressive disorder in Alzheimer’s disease : findings from two databases" 13 : 8-12, 2002

29 Devier DJ, "Predictive utility of type and duration of symptoms at initial presentation in patients with mild cognitive impairment" 30 : 238-244, 2010

30 Rabins PV, "Practical dementia care" Oxford University Press 1999

31 Palmer AM, "Possible neurotransmitter basis of behavioral changes in Alzheimer’s disease" 23 : 616-620, 1988

32 Porsteinsson AP, "Placebo-controlled study of divalproex sodium for agitation in dementia" 9 : 58-66, 2001

33 Lyketsos CG, "Physical aggression in dementia patients and its relationship to depression" 156 : 66-71, 1999

34 Teng E, "Neuropsychiatric symptoms are associated with progression from mild cognitive impairment toAlzheimer’s disease" 24 : 253-259, 2007

35 Gareri P, "Neuropharmacology of depression in aging and age-related diseases" 1 : 113-134, 2002

36 Zubenko GS, "Neurochemical correlates of major depression in primary dementia" 47 : 209-214, 1990

37 Barnes DE, "Mid-life versus late-life depressive symptoms and risk of dementia : differential effects for Alzheimer’s disease and vascular dementia" 69 : 493-498, 2012

38 Roth M, "Meclobemide in elderly patients with cognitive decline and depression. An international double-blind, placebocontrolled trial" 168 : 149-157, 1996

39 Forsell Y, "Major depression in a population of demented and nondemented old people : prevalence and correlates" 46 : 27-30, 1998

40 Lyketsos CG, "Major and minor depression in Alzheimer’s disease : prevalence and impact" 9 : 556-561, 1997

41 Hamilton, "M A rating scale for depression" 23 : 56-62, 1960

42 Blin J, "Loss of brain 5HT2 receptors in Alzheimer’s disease: In vivo assessment with positron emission tomography and 18F setoperone" 116 : 497-510, 1993

43 Levy ML, "Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer’s disease" 153 : 1438-1443, 1996

44 Rapp MA, "Increased neurofibrillary tangles in patients with Alzheimer’s disease with comorbid depression" 16 : 168-174, 2008

45 Payne J, "Incidence, prevalence, and outcomes of depression in residents of a long term care facility with dementia" 7 : 247-253, 2002

46 Gauthier S, "Functional, cognitive, and behavioral effects of donepezil in patients with moderate Alzheimer’s disease" 18 : 347-354, 2002

47 Fuhrer R, "Exploring sex differences in the relationship between depressive symptoms and dementia incidence : prospective results from the PAQUID Study" 51 : 1055-1063, 2003

48 Teri L, "Exercise plus behavioral management in patients with Alzheimer disease : a randomized controlled trial" 290 : 2015-2022, 2003

49 Tariot PN, "Efficacy and tolerability of carbamazepine for agitation and aggression in dementia" 155 : 54-61, 1998

50 Byers AL, "Dysthymia and depression increase risk of dementia and mortality among older veterans" 20 : 664-672, 2012

51 Reifler BV, "Doubleblind trial of Imipramine in Alzheimer’s disease patients with and without depression" 146 : 45-49, 1989

52 Gatz JL, "Do depressive symptoms predict Alzheimer’s disease and dementia?" 60 : 744-747, 2005

53 American Psychiatric Association, "Diagnostic and Statistical Manual ofMental Disorders" American Psychiatric Press 2000

54 Teng E, "Diagnosing depression in Alzheimer’s disease with the national institute of mental health provisional criteria" 16 : 469-477, 2008

55 Yesavage JA, "Development and validation of a geriatric depression screening scale: a preliminary report" 17 : 37-49, 1983

56 Dal Forno G, "Depressive symptoms, sex, and risk for Alzheimer’s disease" 57 : 381-387, 2005

57 Wilson RS, "Depressive symptoms, cognitive decline, and risk of AD in older persons" 59 : 364-370, 2002

58 Wilson RS, "Depressive symptoms, clinical AD, and cortical plaques and tangles in older persons" 61 : 1102-1107, 2003

59 Holtzer R, "Depressive symptoms in Alzheimer’s disease : natural course and temporal relation to function and cognitive status" 53 : 2083-2089, 2005

60 Saczynski JS, "Depressive symptoms and risk of dementia : the Framingham Heart Study" 75 : 35-41, 2010

61 Geerlings MI, "Depressive symptoms and risk of Alzheimer’s disease in more highly educated older people" 48 : 1092-1097, 2000

62 Wilson RS, "Depressive symptoms and cognitive decline in a community population of older persons" 75 : 126-129, 2004

63 Heun R, "Depression in Alzheimer’s disease: is there a temporal relationship between the onset of depression and the onset of dementia?" 17 : 254-258, 2002

64 Green RC, "Depression as a risk factor for Alzheimer disease : the MIRAGE Study" 60 : 753-759, 2003

65 Andersen K, "Depression and the risk of Alzheimer disease" 16 : 233-238, 2005

66 Becker JT, "Depressed mood is not a risk factor for incident dementia in a communitybased cohort" 17 : 653-663, 2009

67 Devanand DP, "Depressed mood and the incidence of Alzheimer’s disease in elderly living in the community" 53 : 175-182, 1996

68 Alexopoulos GS, "Cornell Scale for Depression in Dementia" 23 : 271-284, 1988

69 Katz IR, "Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial" 60 : 107-115, 1999

70 DeRubeis RJ, "Cognitive therapy vs medications in the treatment of moderate to severe depression" 62 : 409-416, 2005

71 Munro CA, "Cognitive response to pharmacological treatment for depression in Alzheimer disease : secondary outcomes from the depression in Alzheimer’s disease study(DIADS)" 12 : 491-498, 2004

72 Sultzer DL, "Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: Phase 1 outcomes from the CATIEAD effectiveness trial" 165 : 844-854, 2008

73 Kwak YT, "Clinical characteristics according to depression screening tools in patients with Alzheimer’s disease: view from self, caregiver-reported and drug-intervention pattern" 13 : 701-707, 2013

74 Forstl H, "Clinical and neuropathological correlates of depression in Alzheimer’s disease" 22 : 877-884, 1992

75 곽용태, "Clinical Characteristics of Behavioral and Psychological Symptoms in Patients with Drug-naïve Alzheimer’s Disease" 대한치매학회 11 (11): 87-94, 2012

76 Zubenko GS, "Biological correlates of clinical heterogeneity in primary dementia" 6 : 77-93, 1992

77 Teri L, "Behavioral treatment of depression in dementia patients : a controlled clinical trial" 52 : 159-166, 1997

78 Debruyne H, "Audenaert K, De Deyn PP, et al. Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment?" 24 : 556-562, 2009

79 Harwood DG, "Association between premorbid history of depression and current depression in Alzheimer’s disease" 12 : 72-75, 1999

80 Irie F, "Apolipoprotein E epsilon4 allele genotype and the effect of depressive symptoms on the risk of dementia in men : the Honolulu-Asia Aging Study" 65 : 906-912, 2008

81 Pinheiro D, "Anticonvulsantmood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)" 34 : 409-415, 2008

82 Beck AT, "An inventory for measuring depression" 4 : 561-571, 1961

83 Whitford GM, "Alzheimer’s disease and serotonin: a review" 15 : 133-142, 1986

84 Nelson JC, "A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia" 59 : 577-585, 2011

85 de Vasconcelos Cunha UG, "A placebo-controlled doubleblind randomized study of venlafaxine in the treatment of depression in dementia" 24 : 36-41, 2007

86 Petracca GM, "A doubleblind placebocontrolled study of Fluoxetine in depressed patients with Alzheimer’s disease" 13 : 233-240, 2001

87 Petracca GM, "A double-blind, placebocontrolled study of fluoxetine in depressed patients with Alzheimer’s disease" 13 : 233-240, 2001

88 Petracca G, "A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer’s disease" 8 : 270-275, 1996

89 Zubenko GS, "A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer’s disease" 160 : 857-866, 2003

90 Reisberg B, "A Behavioral symptoms in Alzheimer’s disease : phenomenology and treatment" 48 : 9-15, 1987